Search Videos and More
News
Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments
Evaluating new medical therapies in people through a rigorous, systematic process, known as a clinical trial, is the pinnacle of clinical research and the primary mechanism through which novel treatments are proven safe and effective in cancer — or any other disease.
News
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Since its introduction in the 1970s, tamoxifen has significantly improved survival rates for millions of patients with estrogen receptor–positive breast cancer.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science
Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.
News
Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions.
News
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Results from this study show that already approved precision medicines have the potential benefit for children with FGFR-altered gliomas.
News
TILs: What Are They and How Are They Used in Cancer Treatment?
Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer.
News
Modified Personalized Cancer Vaccine Generates Powerful Immune Response
Dana-Farber researchers designed a novel formulation and delivery approach for the NeoVax personalized cancer vaccine and observed strong vaccine-specific immune responses in patients with melanoma.
News
Cell Density Speaks Volumes About Cancer Treatment Choices
As powerful as modern cancer medicines are, they don’t work for everyone. What if there were a quick test doctors could perform on an individual person’s cancer to help determine which approved treatment would work best for them?
News
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
News
Double Negative in Cells Could Undermine PARP Inhibitors
There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.